Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-475-60
Published December 18, 2024 · Recall initiated: December 12, 2024
Summary
FDA records drug Class II recall D-0130-2025, published December 18, 2024 and initiated December 12, 2024. Recalling firm: Ascend Laboratories, LLC; Status: Ongoing; Reported quantity: 10,444 bottles; Lot: Lot #: 24142192, 24142193, 24142194, Exp. Date April 30, 2026; 24142463, Exp. Date May 31, 2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
What to do
Voluntary: Firm initiated · Letter
Get an email if DABIGATRAN ETEXILATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- DABIGATRAN ETEXILATE
- Manufacturer
- Ascend Laboratories, LLC
- Distributor
- Nationwide within the United States
- UPC
- 0367877624600
- Lot
- Lot #: 24142192, 24142193, 24142194, Exp. Date April 30, 2026; 24142463, Exp. Date May 31, 2026;
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDADabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only,August 5, 2026
- FDADabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only,August 5, 2026
- FDADabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx only,August 5, 2026
- FDADabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories,July 29, 2026
- FDADabigatran Etexilate, 75 mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd.,December 18, 2024
- FDALevothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 100 Tablets per carton (10 unit dose blister cards of 10December 18, 2024
Questions about this recall
Was Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-475-60 recalled?
Yes. FDA published recall D-0130-2025 on December 18, 2024. Reported hazard: CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: DABIGATRAN ETEXILATE. UPC: 0367877624600.